Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + capecitabine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Axitinib + capecitabine is a combination of two oral small molecule drugs used in oncology clinical trials for advanced solid tumors. Axitinib is a potent and selective second-generation tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), thereby inhibiting angiogenesis, tumor growth, and metastasis. Capecitabine is an orally administered prodrug of 5-fluorouracil (5-FU), which acts as an antimetabolite by interfering with DNA synthesis through inhibition of thymidylate synthase and incorporation into DNA and RNA. The combination has been studied in phase I trials for safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with advanced solid tumors[1][4]. Both agents are approved individually for various cancers; their combination aims to enhance efficacy without significant additive toxicity.
- Other names
- none
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on axitinib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + capecitabine.